Benuvia Operations, LLC (Benuvia) and PharmaCielo Ltd. (PharmaCielo) announced a strategic partnership to produce cGMP pharmaceutical-grade Active Pharmaceutical Ingredients ("APIs") for the global market, including Brazil, Australia, Europe and U.S.A. (the "Strategic Partnership"). As part of the Strategic Partnership, PharmaCielo will be responsible for the cultivation of cannabis and hemp under Good Agricultural and Collection Practice ("GACP") conditions in Colombia, and Benuvia will leverage its FDA registered, and DEA licensed (schedules I-V) cGMP development manufacturing facility in Austin, Texas, to produce final products. To both companies' knowledge, this is an industry-first partnership to provide Seed-to-Pharma products globally where cGMP and its European equivalent EU-GMP certification are must haves.

This model will emphasize quality and compliance as well as sustainable and ethical sourcing and represents a significant improvement in controlling quality throughout the entire supply chain. The partnership extends beyond mere manufacturing; it encompasses a shared vision to explore and offer the market innovative finished dose form services. This initiative will focus on producing cGMP and EU-GMP compliant pharmaceutical products, a step forward in meeting the growing global demand for high-quality, reliable medicinal cannabis products, produced under strict standards.